최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.28 no.3, 2018년, pp.181 - 187
김승민 (연세대학교의료원 세브란스병원 약무국) , 이윤선 (연세대학교의료원 세브란스병원 약무국) , 김재송 (연세대학교의료원 세브란스병원 약무국) , 김수현 (연세대학교의료원 세브란스병원 약무국) , 손은선 (연세대학교의료원 세브란스병원 약무국) , 유철주 (연세대학교 세브란스병원 소아혈액종양과)
Background: Posaconazole is a broad-spectrum triazole antifungal agent and the most recommended prophylactic antifungal agent for patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. In this study, we evaluated the status and effectiveness of posaconazole as a prophylactic a...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
백혈병 환자의 주요한 사망 요인은? | 항암화학요법을 받는 백혈병 환자의 주요한 사망 요인 중 하나는 Candida 종 또는 Aspergillus 종에 의한 침습적 진균감염증(invasive fungal disease, 이하 IFD)이다.1) 새로운 항진균제들이 사용되고 있으나 여전히 IFD의 사망률은 높으며,2)특히 관해유도 요법 중인 급성골수성백혈병(acute myeloid leukemia, 이하 AML) 환자는 IFD 고위험군으로 분류된다. | |
진균감염증 고위험군으로 분류되는 환자는? | 항암화학요법을 받는 백혈병 환자의 주요한 사망 요인 중 하나는 Candida 종 또는 Aspergillus 종에 의한 침습적 진균감염증(invasive fungal disease, 이하 IFD)이다.1) 새로운 항진균제들이 사용되고 있으나 여전히 IFD의 사망률은 높으며,2)특히 관해유도 요법 중인 급성골수성백혈병(acute myeloid leukemia, 이하 AML) 환자는 IFD 고위험군으로 분류된다. 따라서 IFD를 줄이기 위해 항진균제를 이용한 예방요법이 시행되고 있으며예방적 항진균제로 posaconazole이 가장 추천된다. | |
IFD를 줄이기위해 가장 추천되는 향진균제는? | 1) 새로운 항진균제들이 사용되고 있으나 여전히 IFD의 사망률은 높으며,2)특히 관해유도 요법 중인 급성골수성백혈병(acute myeloid leukemia, 이하 AML) 환자는 IFD 고위험군으로 분류된다. 따라서 IFD를 줄이기 위해 항진균제를 이용한 예방요법이 시행되고 있으며예방적 항진균제로 posaconazole이 가장 추천된다.2,3) 관해유도 요법 중인 AML 및 myelodysplastic syndrome (이하 MDS) 성인에서 posaconazole 투여군은 IFD 발생률이 2%로 나타나, fluconazole 투여군 8% 및 itraconazole 투여군 10%에 비해 유의하게 낮았다(p<0. |
Cuenca EM, Bernal ML, Buitrago MJ, et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicmb Agents 2008;32(2):143-7.
Berking S, Doedens D, Horns H, et al. Antifungal prophylaxis in newly diagnosed AML patients adherence to guidelines and feasibility in a real life setting. Mycoses 2017;60(9):600-6.
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59.
Jung DS, Tverdek FP, Kontoyiannis DP, et al. Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. Antimicrob Agents Chemother 2014;58(11):6993-5.
Durani U, Tosh PK, Barreto JN, et al. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension. Antimicrob Agents Chemother 2015; 59(8):4914-8.
Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48(10):1441- 58.
Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53(3):958-66.
Doring M, Muller C, Johann PD, et al. Analysis of Posaconazole as Oral Antifungal Prophylaxis in Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation. BMC Infect Dis 2012;12:263.
De PB, Walsh TJ, Donnelly JP, et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooper- ative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46(12):1813-21.
Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009;52(3):197-205.
Kung HC, Kan LP, Lin HA, et al. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients. Cancer Medicine 2014;3(3):667-73.
Cho SH, Lee DG, Choi SM, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses 2015;58(9):565-71.
Pagano L, Stamouli M, Tumbarello M, et al. Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry. Br J Haematol 2015;170(3):434-9.
Muhlemann K, Wenger C, Zenhuusern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005;19(4):545-50.
Doring M, Cabanillas KM, Queudeville M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol 2017;143(7):1281-92.
Gwee A, Cranswick N, Cranswick N, et al. Posaconazole: Promising but Problematic in Practice in Pediatric Patients. The Pediatr Infect Dis J 2015;34(6):604-6.
Gross BN, Ihorst G, Jung M, et al. Posaconazole Therapeutic Drug Monitoring in the Real-life Setting. Pharmacotherapy 2013;33(10): 1117-25.
Doring M, Eikemeier M, Cabanillas KM, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis 2015;34(6):1189-200.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.